<DOC>
	<DOCNO>NCT02573740</DOCNO>
	<brief_summary>This Phase 1 , multicenter , randomize , double-blind , placebo-controlled , multiple dose study ABT-957 participant mild Alzheimer 's disease ( AD ) Mild Cognitive Impairment ( MCI ) due AD .</brief_summary>
	<brief_title>Safety , Tolerability Effects Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels ABT-957 Subjects With Mild Alzheimer 's Disease Mild Cognitive Impairment</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Female participant must negative result pregnancy test perform serum sample obtain Screening Body Mass Index 18.0 35.0 Screening Meets National Institute Aging Alzheimer 's Association ( NIAAA ) criteria probable Alzheimer 's disease ( AD ) . Meets NIAAA core clinical criterion Mild Cognitive Impairment due AD Use strong inhibitor drug metabolize enzyme within 30 day prior study drug administration Consumption alcohol within 24 hour prior study drug administration Positive screen nonprescribed drug abuse alcohol The participant clinically significant abnormal laboratory value Screening determined investigator History drug alcohol abuse within 6 month prior study drug administration Current diagnosis major depression major psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>